KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40829094.
- Also identified by DOI 10.1200/JCO-25-01439 and PMC identifier 12469856.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the article that accompanies this editorial, the KEYNOTE-585 trial demonstrated that adding pembrolizumab to perioperative chemotherapy with 5-FU and cisplatin in resectable esophagogastric cancer improved pathologic complete response rate but did not significantly improve event free survival over chemotherapy alone, despite trends toward improvement in both event free and overall survival. Although a negative trial, results from KEYNOTE-585 support and reinforce the positive results recently reported from the MATTERHORN Trial, which establishes a new care standard adding durvalumab to perioperative FLOT chemotherapy in resectable esophagogastric cancer.